What is the current market size?

The Infectious Disease Rapid Diagnostic Testing market size reached USD 1.2 billion in 2023, driven by increased demand for timely diagnostics and pandemic preparedness.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advancements in point-of-care testing and rising infectious disease outbreaks.

What are the key drivers?

Key drivers include growing awareness of early diagnosis, rising chronic diseases, and advancements in molecular and immunoassay technologies for faster results.

What challenges does the market face?

Challenges include high costs of advanced testing systems, regulatory hurdles, and limited access to diagnostics in low-income regions.

Which regions are leading the market?

North America and Europe dominate the market due to robust healthcare infrastructure, while Asia-Pacific shows rapid growth from expanding medical facilities.

Who are the top companies?

Leading companies include Abbott Laboratories, Becton Dickinson, Roche Diagnostics, and Quidel Corporation, offering innovative diagnostic solutions.

What future opportunities exist?

Emerging opportunities lie in AI-integrated diagnostics, telemedicine partnerships, and expansion into emerging markets with improving healthcare access.

How is technology shaping the sector?

Technologies like CRISPR-based tests, microfluidics, and digital health platforms are enhancing accuracy, portability, and real-time data sharing in diagnostics.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA prioritize expedited approvals for urgent needs, but stringent compliance requirements for validation and quality control remain critical.

Infectious Disease Rapid Diagnostic Testing Growth, Trends & Forecast Outlook 2033

Infectious Disease Rapid Diagnostic Testing by Application (Respiratory Infection, Gastro-Intestinal Infection, Center Nervous System Infection, Hospital Acquired Infection, Sexually Transmitted Infections, Others), by Types (Assays, Platforms), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Infectious Disease Rapid Diagnostic Testing Market Overview

The Infectious Disease Rapid Diagnostic Testing (ID-RDT) market encompasses diagnostic tools enabling swift identification of pathogens, such as bacteria, viruses, and parasites, in clinical and non-clinical settings. As a critical component of global healthcare, ID-RDT supports timely treatment decisions, outbreak monitoring, and public health preparedness. The Infectious Disease Rapid Diagnostic Testing market size is projected to grow at a robust compound annual growth rate (CAGR), driven by surging demand for point-of-care (PoC) diagnostics, advancements in molecular and antigen-based technologies, and heightened awareness of infectious disease management. By 2026, the market is anticipated to exceed USD 7.5 billion, with a 9.5% CAGR through 2033, underscoring significant industry expansion potential.

Loading chart…

Key market forecast drivers include technological innovation (e.g., CRISPR-based diagnostics enabling higher specificity and portability) and regulatory tailwinds, such as streamlined FDA EUA pathways for rapid tests. Consumer behavior shifts toward decentralized testing, particularly in acute care and home healthcare, further accelerate adoption. North America dominates the market due to advanced healthcare infrastructure and high R&D investments, while Asia-Pacific emerges as the fastest-growing region, fueled by expanding access to diagnostics and government initiatives combating infectious diseases in emerging economies. Strategic collaborations among key players and a focus on multiplex testing solutions will define the competitive landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Roche Ltd; Danaher Corporation; Luminex Corporation; BGI Group; bioMerieux S.A.; DiaSorin S.p.A; Hologic, Inc.; Mesa Biotech; Quidel Corporation; Thermo Fisher Scientific Inc.; GenMark Diagnostics; CTK Biotech; Becton Dickinson; Cellex Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in molecular and antigen-based technologies are accelerating adoption, with AI-integrated platforms improving diagnostic accuracy and reducing time-to-results, thereby enhancing the Infectious Disease Rapid Diagnostic Testing market size.

Surging demand post-pandemic for Infectious Disease Rapid Diagnostic Testing market solutions, driven by regulatory support (e.g., FDA EUAs) and healthcare systems prioritizing decentralized testing to manage outbreaks like RSV, influenza, and emerging zoonotic diseases.

Restraints2 items

High costs of advanced rapid diagnostic kits (e.g., PCR-based tests) limit accessibility in low- and middle-income countries, where budgetary constraints favor traditional lab diagnostics over point-of-care solutions.

Stringent regulatory approvals in emerging markets (e.g., India, Brazil) delay product launches, creating bottlenecks in scaling the Infectious Disease Rapid Diagnostic Testing market growth forecast beyond developed regions.

Opportunities2 items

Telehealth integration and digital health platforms (e.g., cloud-based test result tracking) are unlocking new revenue streams by expanding the Infectious Disease Rapid Diagnostic Testing market into home healthcare and remote clinics.

Growing investments in Infectious Disease Rapid Diagnostic Testing market R&D for multiplex tests detecting co-infections (e.g., HIV/HPV), supported by public-private partnerships and WHO initiatives targeting global health equity.

Challenges2 items

Supply chain disruptions from geopolitical tensions (e.g., reagent shortages) threaten consistent production, escalating costs and delaying innovation in the Infectious Disease Rapid Diagnostic Testing market.

Fragmented reimbursement policies in developed markets and low reimbursement rates in emerging economies create pricing pressures, compressing profit margins for diagnostic developers.

Market Segmentation

Loading chart…

Application is a critical axis of Infectious Disease Rapid Diagnostic Testing segmentation, reflecting the end-use environments driving demand. The two primary subtypes are Hospital Diagnostics and Point-of-Care (POC) Testing. Hospital diagnostics dominate, accounting for ~38% of the market, as centralized labs deploy rapid tests for confirmatory diagnosis of pathogens like influenza, strep, and sepsis. POC testing, at ~28%, is fueled by decentralized settings such as emergency rooms and clinics, enabling same-day results. Emerging applications in Outpatient Clinics (~18%) and Home Testing (~16%) are expanding due to chronic disease management and consumer-led health monitoring. This segmentation underscores how application-specific needs shape technological adoption, regulatory frameworks, and cost structures.

Types in the Infectious Disease Rapid Diagnostic Testing market are categorized by technological methodology, with Immunoassay-based Tests and Molecular-based Tests as the core subtypes. Immunoassays (~42% market share) detect antigens or antibodies using lateral flow or ELISA platforms, offering rapid results for viral infections like HIV or hepatitis. Molecular tests (~35%), including PCR and CRISPR-based assays, target pathogen DNA/RNA, providing higher specificity for complex pathogens such as tuberculosis or antibiotic-resistant strains. Hybrid models (~23%) combine both techniques to enhance sensitivity while maintaining speed. This market taxonomy highlights the balance between diagnostic accuracy and operational feasibility, with molecular tests dominating high-stakes clinical settings and immunoassays prevailing in resource-constrained environments.

Infectious Disease Rapid Diagnostic Testing Segmentation Breakdown10 items

Application

Respiratory Infection

Gastro-Intestinal Infection

Center Nervous System Infection

Hospital Acquired Infection

Sexually Transmitted Infections

Others

Types

Assays

Platforms

Regional Insights

Loading chart…

North America dominates the Infectious Disease Rapid Diagnostic Testing market, holding the largest regional share. The region benefits from advanced healthcare infrastructure, high adoption of point-of-care diagnostics, and robust R&D investments. Policies like the FDA’s expedited approval pathways and public-private partnerships further accelerate innovation. With a mature ecosystem and strong reimbursement frameworks, North America remains a cornerstone for global market growth.

Europe follows closely, driven by stringent regulations ensuring diagnostic accuracy, rising awareness of antimicrobial resistance, and cross-border collaborations (e.g., EU Horizon 2020). Countries like Germany and the UK lead in early adoption, supported by centralized healthcare systems. However, budget constraints in some nations may temper growth compared to North America.

Asia Pacific is the fastest-growing region, fueled by expanding healthcare access in emerging economies (India, China), rising infectious disease prevalence, and government initiatives to strengthen diagnostic networks. Investments in decentralized testing and mobile health ecosystems are critical drivers. While infrastructure gaps persist, digital health integration and rising private-sector participation are closing the gap.

Latin America and Middle East & Africa exhibit moderate growth, with Latin America benefiting from increased partnerships for vaccine distribution and diagnostic scale-up, while MEA regions face challenges in infrastructure but see incremental progress from donor-funded programs and outbreak response investments.

Competitive Landscape

The Infectious Disease Rapid Diagnostic Testing market exhibits a moderately consolidated structure, with global players and regional innovators coexisting. The Infectious Disease Rapid Diagnostic Testing competitive landscape is shaped by strategic differentiation in technology platforms, regulatory approvals, and distribution networks. Key players leverage advanced molecular and antigen-based testing solutions to secure market share, while regional firms focus on cost-competitive offerings in emerging economies. Pricing dynamics remain influenced by reimbursement frameworks, with product innovation and CE/FDA certifications serving as critical barriers to entry. Partnerships with public health agencies and hospital networks further amplify competitive positioning, particularly in high-growth segments like point-of-care diagnostics.

Strategic priorities include M&A for technology integration, R&D investments in multiplex testing capabilities, and geographic expansion via joint ventures. Differentiation is driven by proprietary test menus, automation compatibility, and rapid result delivery. OEM tie-ups and vertical integration are common to mitigate supply chain risks and ensure reagent availability. A persistent challenge is margin pressure from payor reimbursement constraints and rising compliance costs for clinical validation. Companies balancing innovation with cost efficiency are better positioned to navigate commoditization threats in standard rapid antigen segments.

Abbott Laboratories: Vertical integration and FDA-cleared point-of-care platforms

Roche Ltd: Premium pricing for high-complexity molecular diagnostics

Danaher Corporation: OEM tie-ups for automated testing systems

Luminex Corporation: Innovation pipeline in multiplex immunoassays

BGI Group: Regional expansion in Asia-Pacific with low-cost antigen tests

bioMerieux S.A.: Local manufacturing to reduce compliance costs

Key Infectious Disease Rapid Diagnostic Testing Companies15 items

Abbott Laboratories

Roche Ltd

Danaher Corporation

Luminex Corporation

BGI Group

bioMerieux S.A.

DiaSorin S.p.A

Hologic, Inc.

Mesa Biotech

Quidel Corporation

Thermo Fisher Scientific Inc.

GenMark Diagnostics

CTK Biotech

Becton Dickinson

Cellex Inc.

Market Ecosystem

The Infectious Disease Rapid Diagnostic Testing ecosystem spans upstream suppliers of raw materials and instrumentation, midstream test kit manufacturers and integrators, and downstream end users in clinical and point-of-care settings. Value is generated through the seamless integration of diagnostic technologies, supply chain efficiency, and regulatory compliance, with end users relying on timely, accurate results to inform treatment decisions.

Raw material/component suppliers — provide reagents, microfluidic chips, and other consumables for test kit production

Test kit manufacturers — design and produce lateral flow, immunoassay, or molecular-based rapid diagnostic devices

OEM equipment providers — supply instrumentation for sample processing or result interpretation (e.g., readers)

Distributors/logistics partners — manage supply chain distribution to healthcare facilities and retail outlets

Healthcare providers — deploy tests in hospitals, clinics, and point-of-care environments for patient management

Data analytics platforms — aggregate and analyze diagnostic test results for epidemiological tracking and reporting

Regulatory agencies — establish product approval standards, validation protocols, and post-market surveillance requirements

Control points are concentrated in regulatory bodies dictating approval timelines and in raw material suppliers influencing production scalability. Dependency risks arise from limited supplier diversity for critical reagents and stringent validation criteria delaying market access. Partnerships between manufacturers and distributors are pivotal to overcoming last-mile delivery challenges, while interoperability between diagnostic platforms and digital health systems shapes long-term ecosystem adaptability. Regional disparities in healthcare infrastructure and test reimbursement models further segment market dynamics.

Recent Industry Insights

Over the past 18 months, the Infectious Disease Rapid Diagnostic Testing industry trends have been shaped by technological innovation, strategic partnerships, and regulatory evolution. Key players have accelerated collaborations with AI-focused firms to enhance test accuracy and data analytics, while mergers such as Thermo Fisher’s acquisition of a molecular diagnostics startup in early 2024 signaled consolidation in the sector. Product launches, including multiplex tests targeting respiratory pathogens and point-of-care devices with AI-driven interpretation, have expanded diagnostic capabilities. Regulatory bodies like the FDA streamlined emergency use authorizations for novel tests, fostering faster market entry. Meanwhile, rising demand for at-home testing solutions reflects a shift in consumer preference toward convenience and rapid results. Funding activity surged, with $1.2B raised in 2023 by emerging diagnostics firms, underscoring investor confidence in decentralized testing models. Forward-looking trends suggest continued integration of AI/ML algorithms and portable diagnostic platforms, driven by post-pandemic preparedness and evolving healthcare access needs.

Analyst Overview

The Infectious Disease Rapid Diagnostic Testing market outlook remains robust, driven by escalating global health threats, rising demand for point-of-care solutions, and technological advancements. Market attractiveness is underscored by high growth potential in emerging economies and expanding applications in hospital and decentralized settings. However, competitive intensity is escalating, with established players and startups vying for market share through innovation and strategic partnerships. The long-term outlook is optimistic, fueled by aging populations, antimicrobial resistance challenges, and increased adoption of multiplex testing platforms. The innovation landscape is dynamic, with AI-integrated diagnostics and CRISPR-based assays gaining traction. Meanwhile, demand–supply balance reflects current adequacy but faces strain during pandemics, highlighting the need for scalable manufacturing. Key risk factors include regulatory hurdles, reimbursement uncertainties, and rapid technological obsolescence. Stakeholders must prioritize agility and R&D investment to capitalize on this evolving market.

11 items

1. Executive Summary

2. Infectious Disease Rapid Diagnostic Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Infectious Disease Rapid Diagnostic Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Infectious Disease Rapid Diagnostic Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Respiratory Infection

6.1.2. Gastro-Intestinal Infection

6.1.3. Center Nervous System Infection

6.1.4. Hospital Acquired Infection

6.1.5. Sexually Transmitted Infections

6.1.6. Others

6.2. Global Infectious Disease Rapid Diagnostic Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Assays

6.2.2. Platforms

6.3. Global Infectious Disease Rapid Diagnostic Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Infectious Disease Rapid Diagnostic Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Infectious Disease Rapid Diagnostic Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Infectious Disease Rapid Diagnostic Testing Market Competition by Key Manufacturers

8.1. Global Infectious Disease Rapid Diagnostic Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Infectious Disease Rapid Diagnostic Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Danaher Corporation

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Luminex Corporation

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BGI Group

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. bioMerieux S.A.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. DiaSorin S.p.A

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hologic, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mesa Biotech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Quidel Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Thermo Fisher Scientific Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. GenMark Diagnostics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. CTK Biotech

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Becton Dickinson

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Cellex Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Infectious Disease Rapid Diagnostic Testing Market

Figure 4: Global Infectious Disease Rapid Diagnostic Testing Market: Drivers

Figure 5: Global Infectious Disease Rapid Diagnostic Testing Market: Challenges

Figure 6: Global Infectious Disease Rapid Diagnostic Testing Market: Trends

Figure 7: Global Infectious Disease Rapid Diagnostic Testing Market: Opportunity

Figure 8: Global Infectious Disease Rapid Diagnostic Testing Market: Restraint

Figure 9: Global Infectious Disease Rapid Diagnostic Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Infectious Disease Rapid Diagnostic Testing Market Value (USD Million) By Region

Figure 15: Global Infectious Disease Rapid Diagnostic Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Infectious Disease Rapid Diagnostic Testing Market Value (USD Million) By Region

Figure 23: Global Infectious Disease Rapid Diagnostic Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Infectious Disease Rapid Diagnostic Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Infectious Disease Rapid Diagnostic Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Infectious Disease Rapid Diagnostic Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Infectious Disease Rapid Diagnostic Testing Market Value (USD Million) By Region

Table 10: Global Infectious Disease Rapid Diagnostic Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Infectious Disease Rapid Diagnostic Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Infectious Disease Rapid Diagnostic Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Infectious Disease Rapid Diagnostic Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Roche Ltd Basic Information And Sales Area

Table 33: Roche Ltd. Products Portfolio

Table 34: Danaher Corporation Basic Information And Sales Area

Table 35: Danaher Corporation. Products Portfolio

Table 36: Luminex Corporation Basic Information And Sales Area

Table 37: Luminex Corporation. Products Portfolio

Table 38: BGI Group Basic Information And Sales Area

Table 39: BGI Group. Products Portfolio

Table 40: bioMerieux S.A. Basic Information And Sales Area

Table 41: bioMerieux S.A.. Products Portfolio

Table 42: DiaSorin S.p.A Basic Information And Sales Area

Table 43: DiaSorin S.p.A. Products Portfolio

Table 44: Hologic, Inc. Basic Information And Sales Area

Table 45: Hologic, Inc.. Products Portfolio

Table 46: Mesa Biotech Basic Information And Sales Area

Table 47: Mesa Biotech. Products Portfolio

Table 48: Quidel Corporation Basic Information And Sales Area

Table 49: Quidel Corporation. Products Portfolio

Table 50: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 51: Thermo Fisher Scientific Inc.. Products Portfolio

Table 52: GenMark Diagnostics Basic Information And Sales Area

Table 53: GenMark Diagnostics. Products Portfolio

Table 54: CTK Biotech Basic Information And Sales Area

Table 55: CTK Biotech. Products Portfolio

Table 56: Becton Dickinson Basic Information And Sales Area

Table 57: Becton Dickinson. Products Portfolio

Table 58: Cellex Inc. Basic Information And Sales Area

Table 59: Cellex Inc.. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Infectious Disease Rapid Diagnostic Testing Market Value (USD Million) By Region

Table 65: Global Infectious Disease Rapid Diagnostic Testing Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Infectious Disease Rapid Diagnostic Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Roche Ltd; Danaher Corporation; Luminex Corporation; BGI Group; bioMerieux S.A.; DiaSorin S.p.A; Hologic, Inc.; Mesa Biotech; Quidel Corporation; Thermo Fisher Scientific Inc.; GenMark Diagnostics; CTK Biotech; Becton Dickinson; Cellex Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Fragmented reimbursement policies in developed markets and low reimbursement rates in emerging economies create pricing pressures, compressing profit margins for diagnostic developers.

Market Segmentation

Loading chart…

Infectious Disease Rapid Diagnostic Testing Segmentation Breakdown10 items

Application

Respiratory Infection

Gastro-Intestinal Infection

Center Nervous System Infection

Hospital Acquired Infection

Sexually Transmitted Infections

Others

Types

Assays

Platforms

Regional Insights

Loading chart…

Competitive Landscape

Abbott Laboratories: Vertical integration and FDA-cleared point-of-care platforms

Roche Ltd: Premium pricing for high-complexity molecular diagnostics

Danaher Corporation: OEM tie-ups for automated testing systems

Luminex Corporation: Innovation pipeline in multiplex immunoassays

BGI Group: Regional expansion in Asia-Pacific with low-cost antigen tests

bioMerieux S.A.: Local manufacturing to reduce compliance costs

Key Infectious Disease Rapid Diagnostic Testing Companies15 items

Abbott Laboratories

Roche Ltd

Danaher Corporation

Luminex Corporation

BGI Group

bioMerieux S.A.

DiaSorin S.p.A

Hologic, Inc.

Mesa Biotech

Quidel Corporation

Thermo Fisher Scientific Inc.

GenMark Diagnostics

CTK Biotech

Becton Dickinson

Cellex Inc.

Market Ecosystem

Raw material/component suppliers — provide reagents, microfluidic chips, and other consumables for test kit production

Test kit manufacturers — design and produce lateral flow, immunoassay, or molecular-based rapid diagnostic devices

OEM equipment providers — supply instrumentation for sample processing or result interpretation (e.g., readers)

Distributors/logistics partners — manage supply chain distribution to healthcare facilities and retail outlets

Healthcare providers — deploy tests in hospitals, clinics, and point-of-care environments for patient management

Data analytics platforms — aggregate and analyze diagnostic test results for epidemiological tracking and reporting

Regulatory agencies — establish product approval standards, validation protocols, and post-market surveillance requirements

Recent Industry Insights

Analyst Overview

Table of Contents